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Abstract
Objectives: To investigate the cognitive effects of high-
dose oral estrogen alone or in combination with oral
methyltestosterone in postmenopausal women. Meth-
ods: Participants were tested with a randomized, double-
blind design on the Identical Pictures, Cube Compari-
sons, Building Memory and Shape Memory tasks before
and after 4 months of hormone treatment. Results:
Women receiving estrogen and methyltestosterone
maintained a steady level of performance on the Build-
ing Memory task, whereas those receiving estrogen
alone showed a decrease in performance. Conclusions:
These results indicate that the addition of testosterone
to high-dose estrogen replacement exerts a protective
effect on memory performance in postmenopausal
women. 
Copyright © 2002 S. Karger AG, Basel
Some evidence suggests that cognition can be in-
fluenced by androgen actions in women. A placebo-con-
trolled investigation of the effects of a single oral dose
(0.5 mg) of testosterone on cognition in young women
resulted in improved delayed-recall performance on an
object-location memory test. Among female-to-male
transsexuals, performance on spatial ability tasks im-
proved following high-dose testosterone treatment to ini-
tiate phenotypic masculinization [2–4].
Several correlation studies have identified relation-
ships between endogenous androgen levels and cognition
in women. Premenopausal women with high testosterone
levels outperformed those with low levels on spatial tasks
[5]. Spatial performance was superior among women
tested in the morning when testosterone concentration
peaks compared to later in the day when testosterone pro-
duction decreases [6]. Women with congenital adrenal
hyperplasia, who are exposed to abnormally high concen-
trations of adrenal androgens prenatally (and postnatally
if not compliant with treatment) exhibit enhanced perfor-
mance on a variety of spatial tasks [7]. A large study of
neuropsychological performance and hormonal milieu in
older women revealed that participants with higher tes-
tosterone levels outperformed those with lower levels on
mental status scores [8].
Some studies of androgen treatment, however, have
failed to identify a clear relationship between these ste-
roid hormones and cognitive performance in women. Sur-
gically menopausal women improved in performance on
tests of memory and logical reasoning following sex ste-
roid replacement, regardless of estrogen and/or androgen
replacement [9]. Furthermore, a double-blind, placebo-
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controlled study involving DHEA treatment (50 mg daily
for 2 weeks) in postmenopausal women revealed that cog-
nitive performance was not affected by androgen treat-
ment despite significant increases in DHEA, androstene-
dione and testosterone levels [10]. Finally, in a correlation
study, investigators failed to observe any association be-
tween endogenous levels of the weak adrenal androgen
DHEA and neuropsychological test performance in wom-
en [11].
The purpose of the present study was to examine the
impact of 4 months of testosterone or placebo treatment
in conjunction with high-dose estrogen replacement on
cognitive performance in postmenopausal women. Our
hypotheses were that postmenopausal women receiving
methyltestosterone treatment in conjunction with high-
dose estrogen treatment for a period of 4 months would
perform better on cognitive tasks containing a visuospa-
tial component compared to women receiving high-dose
estrogen only. We also predicted that the addition of
methyltestosterone to high-dose estrogen treatment would
fail to bestow a benefit in performing female-biased tasks
(Identical Pictures).
Methods
Participants
Participants included 26 women (mean age 58, range 46–77
years) recruited from paid advertisements to take part in a larger
study concerning the potential role of testosterone on muscle mass,
bone density and cardiovascular risk factors in postmenopausal
women. Inclusion criteria consisted of a bilateral oopherectomy, or a
cessation of menstrual periods for at least 6 months with a conse-
quent increase in FSH concentration (1 30 mIU/ml). All participants
received 0.625 mg conjugated estrogen-replacement therapy daily,
with adjuvant progestin if a uterus was present, for at least 3 months
to be considered for inclusion prior to recruitment (run-in). Three
women were excluded for having unusually high estradiol concentra-
tions at baseline (mean 244 pg/ml) which exceeded that of partici-
pants (mean 85.5 pg/ml) by 3 standard deviations. These women
were excluded because of the possibility that they did not correctly
adhere to the 3-month run-in estrogen-replacement therapy require-
ment.
Prior to study enrollment, women were screened for general
health status including blood screening (CBC, blood chemistry) and
breast exams. Women were excluded from enrollment if they met
any of the following: were obese (BMI 130); had uncontrolled dia-
betes (HgbA1c 19%); hypertension (BP 1140/90 mm Hg); had
breast or uterine cancer; had hepatic, renal or cardiac disease; had a
history of hypercholesterolemia, or had received any form of andro-
gen or antidepressant during the 6 months prior to study enrollment.
Further screening of neurologic disorders, mood, SES and level of
education was not conducted.
Approximately half of participants experienced natural meno-
pause and half surgical menopause. All participants received stan-
Table 1. Summary of demographic characteristics at baseline
Characteristic Estratab
(n = 13)
Estratest
(n = 13)
p value
Age, years p 1 0.1
Mean B SD 56.4B5.9 59.8B8.2
Range 46–67 50–77
Race p 1 0.1
White 11 (84.6%) 11 (84.6%)
Hispanic 1 (7.7%) 0 (0.0%)
Black 1 (7.7%) 2 (15.4%)
Menopause p 1 0.1
Surgical 6 (46.2%) 5 (38.5%)
Natural 7 (53.8%) 8 (61.5%)
p values for comparisons of the distributions of race and meno-
pause between treatments are based on a ¯2 test. p -values for com-
parison of the distributions of age between treatments are based on a
t test.
dard estrogen-replacement therapy (0.625 mg conjugated estrogens)
for at least 3 months prior to enrollment. The race of participants is
shown in table 1. No differences were observed between groups for
these variables.
Procedure
The design was a randomized, double-blind study. Based on a
predetermined randomization code unknown to the experimenters
or participants prior to study completion, women were assigned to
receive one of two treatments. One treatment, Estratab®, consisted of
a daily oral preparation of estrogen in the form of 1.25 mg esterified
estrogen (E group) for 4 months. The second treatment, Estratest®,
consisted of a daily oral preparation of estrogen plus methyltestoste-
rone in the form of 1.25 mg esterified estrogen + 2.50 mg methyltes-
tosterone (E+T group) for 4 months. The oral estrogen dose was dou-
bled upon entry into the study to minimize unwanted virilization
such as hirsutism or clitoral enlargement in the E+T group. Medica-
tion was taken for both treatment groups between 08.00 and 10.00 h.
Participants were tested twice, once before treatment (session 1) and
again following 4 months of E or E+T treatment (session 2). Testing
occurred between 08.00 and 10.00 h at an outpatient clinic at the
Johns Hopkins Hospital.
Medication was provided by Solvay Pharmaceuticals, Inc. (Mar-
rietta, GA). No progestin was administered during the study period,
however women with a uterus were administered progestin (10 mg
daily) for 14 days per month following study completion. The
research reported here was approved by the Joint Committee of Clin-
ical Investigations of the Johns Hopkins University, School of Medi-
cine (Baltimore, MD). Written, informed consent was obtained from
all subjects prior to participation.
Endocrine Assays
All participants fasted for a minimum of 12 h before morning
blood draw. Blood was drawn with serum separator tubes for hor-
mone assays and blood chemistry. Sera and plasma were separated at
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4°C for 15 min 2,000 rpm. Sera were stored at –70°C until analyzed,
for a period of up to 7 months. Samples were analyzed by Quest
Diagnostics Laboratory (Owings Mills, MD). For each test, all sam-
ples were analyzed in a single assay. The radioimmunoassay proce-
dure for LH consisted of a two-site chemiluminometric immunoas-
say for intact LH with a 3.1% intra-assay coefficient of variation and
sensitivity of 4.2 mIU/ml. Radioimmunoassay for FSH consisted of
a two-site chemiluminometric immunoassay for intact FSH with a
2.6% intra-assay coefficient of variation and a sensitivity of 4.0 mIU/
ml. Sequential radioimmunoassay with bound/free separation by
PEG-accelerated second antibody without extraction, and 5.5%
intra-assay coefficient of variation and a sensitivity of 16.9 pg/ml was
performed for estradiol. A competitive radioimmunoassay for total
testosterone (TT) consisted of double antibody/PEG-precipitated
separation with organic extract and celite chromatography pretreat-
ment and tritiated testosterone added to correct for extraction recov-
ery, with a 9.2% intra-assay coefficient of variation and a sensitivity
of 13.8 ng/dl. Radioimmunoassay for free testosterone (FT) incu-
bated the sample with 3H-testosterone, and testosterone bound to sex
hormone-binding globulin (SHBG) was precipitated with ammoni-
um sulfate. The aliquot was counted and percent FF estimated with
the equation free = %free ! TT, with a 10% intra-assay coefficient of
variation and a sensitivity of 5.0 ng/dl. A competitive radioimmu-
noassay for SHBG used double-antibody/PEG-precipitation separa-
tion with a 4.8% intra-assay coefficient of variation and a sensitivity
of 16 nmol/l.
Cognitive Measures
All cognitive tasks were taken with permission from the kit of
Factor-Referenced Cognitive Tests (Educational Testing Services,
Princeton NJ). Tasks were administered in a fixed order (Identical
Pictures, Cube Comparisons, Building Memory, Shape Memory) for
each participant at each test session by an experienced technician. A
task that favors females such as Identical Pictures (with a low-
medium effect size of approximately 0.2) and a task that favors males
such as Cube Comparisons (with a stronger effect size of approxi-
mately 1.0 or greater) were used as it seemed reasonable that these
might be sensitive to sex hormone treatment in postmenopausal
women [12]. Memory tests were employed in light of reports that sex
hormone replacement improves verbal and figural memory in post-
menopausal women [13, 14]. The Building Memory test was chosen
because males typically outperform females on measures of route
learning as well as knowledge of Euclidean properties [15]. The Shape
Memory test was administered to assess learning and memory for
abstract visuospatial stimuli, as women have been shown to outper-
form men on remembering positions and matching objects as well as
nonsense shapes [16, 17].
Identical Pictures Test [18] (Copyright 1962, 1975 ETS). This test
measures the ability to match identical items (e.g., faces, animals,
houses) from a series of similar-appearing line drawings, and is docu-
mented to elicit a sex difference in performance that favors females
[19]. Participants were allotted 1.5 min to complete 48 test items.
The dependent measure is the number of correct matches.
Cube Comparisons Test [18] (Copyright 1962, 1976 ETS). This
test measures the ability to mentally rotate a line drawing of a 3-
dimensional cube, and is documented to elicit a sex difference in
favor of males. Participants were allotted 3 min to mentally rotate 21
test items. The dependent measure is the correct identification of the
mental rotation of each test item from series of forced-choice line
drawings.
Building Memory Test [18] (Copyright 1975, ETS). This test mea-
sures the visual memory of building locations on a street map. Partic-
ipants were allotted 4 min to study and memorize a map, followed by
an additional 4 min in which to indicate the correct location of 12
buildings on a test map. The dependent measure is the accurate
placement of the buildings on a test map.
Shape Memory Test [18] (Copyright 1975, 1976 ETS). This test
measures the visual memory of a group of shapes and their position
in relation to each other. Participants were allotted 4 min to study
and memorize a visual scene, followed by another 4 min in which to
respond to 16 test items. The dependent measure is the number of
correct shapes, properly arranged in relation to one another, recog-
nized from a group of forced-choice distracter shapes and arrange-
ments.
Different but comparable test items were used in sessions 1 and 2
for all tasks.
Data Analysis
Differences in task performance and hormone levels between
women receiving E or E+T treatment were assessed with a 2-factor
(treatment group ! test session), mixed analysis of variance for each
cognitive task and hormone measured. Post hoc comparisons were
conducted using Tukey’s method of multiple comparisons. Mean dif-
ferences were considered statistically significant for p ! 0.05.
Results
Endocrine Assays
Hormone levels for each group at each test session are
presented in table 2. As expected, a main effect of test ses-
sion was observed for estradiol concentrations (F(1,24) =
29.7, p ! 0.001), where the mean concentration increased
following treatment for both groups. A main effect of test
session was observed for TT concentrations (F(1,22) =
12.2, p ! 0.005), LH concentrations (F(1,23) = 6.58, p !
0.05), and FSH concentrations (F(1,23) = 6.7, p ! 0.05). A
test session ! treatment group interaction approached
significance for LH concentrations (F(1,23) = 3.0, p =
0.09). Post hoc analysis revealed a decrease in LH concen-
trations for the E+T, but not the E group, across test ses-
sions (p ! 0.05). Finally, a test session ! treatment group
interaction was observed for SHBG concentrations
(F(1,24) = 4.8, p ! 0.05) with mean concentrations
decreasing from session 1 to session 2 for the E+T group.
Cognitive Performance
Identical Pictures. Numerical performance increased
for the E group, and decreased for the E+T group, follow-
ing 4 months of treatment as shown in figure 1 and
table 3. No main effects of test session or treatment were
observed, however a significant treatment by test session
interaction was noted (F(1,24) = 4.41, p ! 0.05).
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Fig. 1. Mean number of correct responses on the Identical Pictures
task. Error bars represent B 1 SEM. No main effects of test session or
treatment group were observed, however a significant session !
treatment interaction was noted.
Fig. 2. Mean number of correct responses on the Building Memory
task. Error bars represent B 1 SEM. Women in the E group showed a
decrease in their performance across test sessions 1 and 2, while
women in the E+T group maintained a steady level of performance.
Table 2. Hormone concentrations for
participants (mean B SEM) E group
session 1 session 2
E+T group
session 1 session 2
Estradiol, pg/ml 85.3B14.8 209.8B19.6 85.8B13.4 283.2B40.7
TT, ng/dl 16.7B2.9 6.7B2.7 16.6B3.1 8.5B1.7
FT, ng/dl 2.0B0.4 2.7B0.9 3.4B0.8 3.3B0.6
LH, mIU/ml 24.6B4.2 22.9B3.1 28.5B4.2 19.4B2.7
FSH, mIU/ml 38.4B7.7 32.1B5.5 40.7B5.6 30.0B4.8
SHBG, nmol/l 43.6B19.7 44B4.7 27.12B7.1 8.51B1.2
Table 3. Scores for the Identical Pictures
test (mean B SEM)
E group E+T group
Session 1 20.5B1.7 24.7B2.3
Session 2 24.2B2.7 21.8B1.8
Due to the large range in ages of the participants, a
MANCOVA with age as a covariate was performed and
revealed the same pattern of results with no main effects
of test session or treatment (F(1,23) = 0.25, p 1 0.05).
Additionally, differences in SHBG concentrations at ses-
sion 1 between groups could potentially contribute to the
baseline difference in performance on the Identical
Pictures task. To address this possible confound, a
MANCOVA was performed with SHBG concentration at
session 1 as a covariate and again revealed no main effects
of test session or treatment (F(1,23) = 1.34, p 1 0.05).
Cube Comparisons. Performance improved for both
groups across test sessions, however this improvement
only approached statistical significance (F(1,23) = 2.949,
p = 0.09). No other effects were significant.
Building Memory. A main effect of test session was
observed, with performance declining across sessions for
both groups (F(1,23) = 14.08, p ! 0.01) as indicated in
table 5 and figure 2. A treatment ! test session interac-
tion was observed (F(1,23) = 6.948, p ! 0.05). Post hoc
comparison revealed that this effect was due to a decrease
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Table 4. Scores for the Cube Comparisons
test (mean B SEM)
E group E+T group
Session 1 5.9B0.6 6.9B1.0
Session 2 7.1B0.8 8.3B1.2
Table 5. Scores for the Building Memory
test (mean B SEM)
E group E+T group
Session 1 7.4B0.7 7.0B0.9
Session 2 5.0B0.7 6.6B0.9
Table 6. Scores for the Shape Memory test
(mean B SEM)
E Group E+T group
Session 1 9.8B0.8 10.8B0.5
Session 2 12.1B1.0 12.2B0.6
in the E group (p ! 0.05) but not the E+T group (p 1 0.1)
across sessions. Post hoc comparison also revealed that
the E and E+T groups did not differ in baseline perfor-
mance on this task (p 1 0.1). No other effects were signifi-
cant.
Shape Memory. Performance improved across test ses-
sions for both the E and E+T groups, (F(1,23) = 7.816, p !
0.05) as shown in table 6. No other effects were signifi-
cant.
Discussion
The present investigation extends our understanding
of sex hormone-replacement therapy on cognitive perfor-
mance in postmenopausal women, to include testosterone
in conjunction with estrogen treatment. Our original hy-
potheses were that postmenopausal women receiving
methyltestosterone treatment in conjunction with high-
dose estrogen treatment would perform better on cogni-
tive tasks containing a visual spatial component com-
pared to women receiving high-dose estrogen alone. We
also predicted that the addition of methyltestosterone to
high-dose estrogen treatment would fail to improve per-
formance on female-biased tasks that do not include a
visual spatial processing component.
Data collected in this study partially support our origi-
nal predictions. Women receiving E+T maintained a
steady level of performance on the Building Memory task
between test sessions, while women receiving E alone
exhibited a decrease in performance. This suggests that
testosterone replacement is protective for performance on
this task in the context of high-dose E replacement in
postmenopausal women. This result is consistent with
previous reports of a male advantage for route learning. It
is possible that Building Memory and route learning tasks
share one or more processing components that are
harmed by high-dose estrogen alone, but protected when
testosterone is included at sufficient levels.
In two tasks, Cube Comparisons and Shape Memory,
performance improved across test sessions for both sub-
ject groups. These results do not support our original
hypothesis, that the E+T group should outperform the E
group on these visual tasks. Due to the necessity of a dou-
bling estrogen dose for both groups in this study, it is
impossible to know if this improved performance was a
result of practice effects, increasing estrogen dose or a
combination of these two factors. It may also be the case
that higher doses of testosterone are required to see the
predicted differences on these tasks. Future studies of this
type should include placebo groups receiving no sex hor-
mone replacement to better understand these patterns of
performance.
As expected, both treatment groups showed a signifi-
cant increase in estradiol concentrations after doubling
their replacement dose of estrogen across test sessions. A
significant decrease in TT production was also observed
following 4 months of treatment for both groups. This can
be explained by the suppression of gonadotropins by the
increased E replacement across test sessions, thus presum-
ably leading to decreased ovarian androgen production
[20]. Although methyltestosterone cannot be measured
with radioimmunoassays developed for TT and FT, it can
be indirectly assessed with LH and SHBG radioimmu-
noassays. In general, SHBG and LH concentrations de-
crease with increased androgens [21, 22], and the E+T
group experienced a decrease in both following 4 months
of methyltestosterone treatment. Post hoc comparison
revealed that this decrease was statistically significant for
LH.
Roughly half of circulating TT is produced either
directly or indirectly from the adrenal glands in women
[23]. Women experience peak adrenal androgen produc-
tion during their early to mid adulthood [24]. If physiolog-
ical concentrations of androgens influence cognitive per-
formance in women, then a decrease in testosterone pro-
duction associated with both normal adrenal aging as well
as menopause could be associated with cognitive changes
in older women. The present study partially supports this
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logic in that testosterone treatment protected against the
decrease in Building Memory performance associated
with estrogen-replacement in postmenopausal women. It
would be of interest to investigate the impact of E+T
replacement on verbal and long-term rote memory perfor-
mance in postmenopausal women [25].
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